Systematic Review and Meta-analysis of Maternal, Natal, and Neonatal Adverse Events of Special Interest following BNT162b2 and mRNA-1273 Gestational Vaccination
This systematic review and meta-analysis of over 467,000 individuals indicates that gestational BNT162b2 and mRNA-1273 vaccination is associated with a reduced risk of neonatal death and NICU admission when administered in the first and second trimesters, respectively, while showing no significant link to major congenital malformations or preterm birth.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Pregnancy is a time of profound biological change, a period where the developing life inside the womb is uniquely sensitive to the world outside. For decades, doctors have approached new medicines and vaccines with extreme caution during this window, often waiting until safety is proven in non-pregnant populations before considering use. This hesitation is understandable; the stakes are high, and the goal is to protect both the mother and the growing child from harm. When the global pandemic arrived, this caution collided with a new reality: the virus itself posed a severe threat to pregnant people, causing more severe illness and worse pregnancy outcomes than in the general population. Vaccines became a critical tool to prevent this danger, but they also introduced a new question that kept many families awake at night. Would the very thing meant to protect them cause unintended harm to the baby's development or the course of the pregnancy?
To answer this, a team of researchers from institutions in Saudi Arabia, the United Kingdom, and Cyprus set out to look at the evidence with a level of detail that had not been seen before. They focused specifically on two of the most widely used mRNA vaccines, the ones developed by Pfizer-BioNTech and Moderna. Rather than grouping all vaccines together or treating the entire pregnancy as a single block of time, they asked a more precise question: does the specific timing of the shot matter? They wanted to know if receiving the vaccine in the first trimester, when the baby's organs are forming, carried different risks than receiving it later. They also wanted to know if the specific type of vaccine mattered. By examining data from fifteen different studies involving nearly half a million vaccinated individuals, they built a picture of what actually happens when these vaccines are given during pregnancy.
The researchers gathered information from a vast array of sources, including medical records from hospitals in the United States, Canada, Europe, Asia, and Australia. They looked for specific outcomes that doctors and parents worry about most: major birth defects, premature birth, the need for a baby to be admitted to a neonatal intensive care unit, and the tragic event of neonatal death. They also examined whether the vaccines influenced the likelihood of a Cesarean section. To ensure their findings were robust, they did not simply average all the numbers together. Instead, they carefully separated the data by the type of vaccine, the trimester in which the vaccine was given, and the specific outcome being measured. This approach allowed them to see if a pattern existed for a specific vaccine at a specific time, rather than getting lost in a general average that might hide important details.
What they found was a reassuring story, one that suggests the vaccines do not cause the harms that many feared. When they looked at major birth defects, which are structural problems present at birth, the data showed no link to the vaccines. Whether the mother received the shot in the first trimester or at any other time, the rate of these defects was the same as in unvaccinated pregnancies. This held true even when they looked specifically at heart defects, a concern that often arises because the heart forms early in pregnancy. The analysis found no evidence that the vaccines increased the risk of these conditions. Similarly, the data did not show an increase in preterm birth, which is when a baby is born before 37 weeks of gestation. The rates of early delivery were consistent between vaccinated and unvaccinated groups, suggesting the vaccines do not trigger early labor.
The picture was equally clear regarding Cesarean deliveries. Some earlier, smaller studies had hinted that vaccinated mothers might be more likely to have a C-section, but this large-scale review found no such connection. The likelihood of needing a surgical delivery was the same regardless of whether the mother had received the vaccine. In fact, for some outcomes, the data pointed in the opposite direction of fear. The researchers observed that babies born to vaccinated mothers were slightly less likely to be admitted to the neonatal intensive care unit, particularly when the mother was vaccinated during the second trimester. They also found a potential signal suggesting a lower risk of neonatal death for those vaccinated in the first trimester.
It is important to understand what these numbers mean in the real world. The researchers were careful to note that finding a lower rate of a bad outcome does not necessarily prove the vaccine directly prevents that outcome. It is possible that vaccinated mothers were healthier to begin with, or that the vaccine protected them from the virus, and it was the absence of the virus that kept the babies safe. The virus itself is known to cause severe complications, so preventing infection is a powerful way to improve outcomes. However, the most critical takeaway from this work is what it ruled out. The study found no evidence that the vaccines cause harm. They do not increase the risk of birth defects, they do not make preterm birth more likely, and they do not force more Cesarean sections.
The study also highlighted the importance of looking at the details. When the researchers relaxed their strict rules and mixed different types of vaccines and different times of pregnancy together, the results remained consistent. This suggests that the safety profile is stable across different scenarios. While the researchers noted that some of the findings, such as the potential reduction in neonatal death, need further confirmation with larger studies, the overall message is one of confidence. The data, drawn from nearly 470,000 individuals across the globe, paints a consistent picture: the mRNA vaccines are safe for use during pregnancy. They protect the mother from a dangerous virus without introducing new risks to the child, offering a path forward for families navigating the complexities of pregnancy in a changing world.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.